A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 165 participants.
Also called NCT07217067
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 165 participants
- Sponsor
- Registry
-
NCT07217067
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, China, Germany, Netherlands, Singapore, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07217067. Randomized; double masking; primary purpose treatment. Start 2025-10-28 (actual); primary completion 2027-09-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- PKN605
- Intervention (Other)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07217067- Content hash
8d07fc8c1850539cccdd3b4bb1de9f4d45e7959cbf53ae7510ac0a42131fe96b